The inter-and intrasubject reproducibility of the metabolite levels of N-acetylaspartate (NAA), creatine (Cr), and choline (Cho), obtained with three-dimensional (3D) multivoxel proton spectroscopy ( 1 H-MRS), was analyzed in eight healthy volunteers. Serial, back-to-back measurements on a phantom showed the methodology and instrumentation to be highly reproducible, with a median coefficient of variation (CV) of 3.8%. In the human brain, the metabolite levels' variability was larger, with intrasubject median CVs for a total of 1876 signal voxels of 13.8%, 18.5%, and 20.1% for NAA, Cr, and Cho, respectively. These variations possibly arise from small, unavoidable, ؎1-2 mm volume-of-interest (VOI) repositioning uncertainties, which vary each 0.75-cm 3 voxel's partial fluid/gray/white-matter fractions. Comparing the CVs between eight subjects in a total of 324 selected voxels gave total interindividual CVs of 15.6%, 23.3%, and 24.4%, compared with intraindividual CVs in the same voxels of 14.4%, 14.8%, and 15.3%, for NAA, Cr, and Cho, respectively. Replacing the signal(s) from each voxel by the average of itself with its six canonical neighbors reduces the intrasubject median CVs to 8.3%, 9.5%, and 9.7%. The measurement uncertainties can be reduced at a cost of either spatial resolution (by using larger voxels Key words: absolute quantification; brain; multivoxel localization; proton spectroscopy; reproducibility 1 H-MRS frequently augments MRI in studies of focal as well as diffuse brain pathologies, e.g., for multiple sclerosis (MS), cancer, AIDS, trauma, Alzheimer's disease (AD), and stroke (1). Due to the progressive nature of these disorders, MRS is usually performed serially, over time, to assess the disease's advance or its response to treatment. The evaluation of the MRS data is based primarily on the comparison of either relative or absolute levels of the three major 1 H-MRS-observable metabolites: NAA, Cr, and Cho, in regions of suspected pathology, with corresponding healthy ones. Reported metabolite variations in these diseases range between 10 -20% for HIV infection and focal epilepsy to upwards of 30% in MS and AD (1).However, to objectively evaluate the significance of such changes, it is necessary to establish how reproducible the measured metabolite levels are in normal controls, both cross-sectionally and temporally. Only then, when changes in suspected region(s) in a patient are significant compared with these normal variations, can one be confident that they represent true pathology and not normal biological fluctuations or intrinsic errors of the instrumentation and method(s).To address the reproducibility issues, we conducted a study to identify and quantify the: 1) stability of the machine and the methodology, using back-to-back measurements on a phantom; 2) intraindividual temporal variations in the brain of a volunteer; and 3) interindividual variations across a cohort of healthy subjects. Previous studies on this topic mostly employed single-voxel MRS techniques (2-5), and more recently, s...